Health

Alphasigma presents the first data of the study on filgotinib for the treatment of active axial spondiloarthritis

BOLOGNA (ITALPRESS) – Alfasigma S.p.A, a global pharmaceutical group, with established skills in rare diseases and specialist therapeutic areas with significant dissatisfied clinical needs, presented 2026 positive results of Phase 3 OLINGUITO clinical study at EULAR Congress. In the study,

Alphasigma presents the first data of the study on filgotinib for the treatment of active axial spondiloarthritis Read More »

Scroll to Top